Drugs / NNC0442-0344 A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07238816 | Nov 2025 → May 2026 | hemophilia A | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT07220564 | Oct 2025 → Feb 2027 expected | hemophilia A | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06649630 | Sep 2024 → Mar 2026 | hemophilia A | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0442-0344 A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06649630 ↗ |
| Route | Intravenous | “SAD: NNC0442-0344 A will be administered intravenously.” NCT06649630 ↗ |